CRINETICS PHARMACEUTICALS IN (CRNX) Stock Overview
NASDAQ:CRNX - US22663K1079 - Common Stock
CRNX Key Statistics, Chart & Performance
The current stock price of CRNX is 30.92 USD. In the past month the price decreased by -0.23%. In the past year, price decreased by -41.82%.
CRNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About CRNX
Company Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 437 full-time employees. The company went IPO on 2018-07-18. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. The company has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Company Info
CRINETICS PHARMACEUTICALS IN
10222 Barnes Canyon Road, Bldg. #2
San Diego CALIFORNIA 92121 US
CEO: R. Scott Struthers
Employees: 437
Phone: 18584506464
CRINETICS PHARMACEUTICALS IN / CRNX FAQ
What is the stock price of CRINETICS PHARMACEUTICALS IN today?
The current stock price of CRNX is 30.92 USD. The price increased by 5.17% in the last trading session.
What is the ticker symbol for CRINETICS PHARMACEUTICALS IN stock?
The exchange symbol of CRINETICS PHARMACEUTICALS IN is CRNX and it is listed on the Nasdaq exchange.
On which exchange is CRNX stock listed?
CRNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CRINETICS PHARMACEUTICALS IN stock?
24 analysts have analysed CRNX and the average price target is 71.88 USD. This implies a price increase of 132.46% is expected in the next year compared to the current price of 30.92. Check the CRINETICS PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CRINETICS PHARMACEUTICALS IN worth?
CRINETICS PHARMACEUTICALS IN (CRNX) has a market capitalization of 2.91B USD. This makes CRNX a Mid Cap stock.
How many employees does CRINETICS PHARMACEUTICALS IN have?
CRINETICS PHARMACEUTICALS IN (CRNX) currently has 437 employees.
What are the support and resistance levels for CRINETICS PHARMACEUTICALS IN (CRNX) stock?
CRINETICS PHARMACEUTICALS IN (CRNX) has a support level at 27 and a resistance level at 31.06. Check the full technical report for a detailed analysis of CRNX support and resistance levels.
Is CRINETICS PHARMACEUTICALS IN (CRNX) expected to grow?
The Revenue of CRINETICS PHARMACEUTICALS IN (CRNX) is expected to grow by 264.58% in the next year. Check the estimates tab for more information on the CRNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CRINETICS PHARMACEUTICALS IN (CRNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRNX, evaluating the profitability, health, valuation and growth aspects
- CRINETICS PHARMACEUTICALS IN (CRNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CRINETICS PHARMACEUTICALS IN (CRNX) Sales and EPS estimates to see what analysts future expectations are.
- CRINETICS PHARMACEUTICALS IN (CRNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CRINETICS PHARMACEUTICALS IN (CRNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CRINETICS PHARMACEUTICALS IN (CRNX) Stock Chart to make your own analysis
- CRINETICS PHARMACEUTICALS IN (CRNX) Latest news and press-releases to stay up to date.
Does CRINETICS PHARMACEUTICALS IN (CRNX) stock pay dividends?
CRNX does not pay a dividend.
When does CRINETICS PHARMACEUTICALS IN (CRNX) report earnings?
CRINETICS PHARMACEUTICALS IN (CRNX) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of CRINETICS PHARMACEUTICALS IN (CRNX)?
CRINETICS PHARMACEUTICALS IN (CRNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.11).
What is the Short Interest ratio of CRINETICS PHARMACEUTICALS IN (CRNX) stock?
The outstanding short interest for CRINETICS PHARMACEUTICALS IN (CRNX) is 14.45% of its float. Check the ownership tab for more information on the CRNX short interest.
CRNX Technical Analysis
CRNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRNX. No worries on liquidiy or solvency for CRNX as it has an excellent financial health rating, but there are worries on the profitability.
CRNX Financial Highlights
Over the last trailing twelve months CRNX reported a non-GAAP Earnings per Share(EPS) of -4.11. The EPS decreased by -8.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.68% | ||
| ROE | -31.57% | ||
| Debt/Equity | 0 |
CRNX Forecast & Estimates
24 analysts have analysed CRNX and the average price target is 71.88 USD. This implies a price increase of 132.46% is expected in the next year compared to the current price of 30.92.
For the next year, analysts expect an EPS growth of -30.76% and a revenue growth 264.58% for CRNX